NeuBase Therapeutics (NBSE)
(Delayed Data from NSDQ)
$0.38 USD
0.00 (0.00%)
Updated May 10, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for NeuBase Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | NA | 0 | 0 | 0 | 0 |
Cost Of Goods | NA | 0 | 0 | 0 | 0 |
Gross Profit | NA | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 0 | 5 | 33 | 27 | 17 |
Income After Depreciation & Amortization | 0 | -5 | -33 | -27 | -17 |
Non-Operating Income | NA | 0 | 0 | 1 | 0 |
Interest Expense | NA | 0 | 0 | 0 | 0 |
Pretax Income | NA | -4 | -34 | -25 | -17 |
Income Taxes | NA | 0 | 0 | 0 | 0 |
Minority Interest | NA | 0 | 0 | 0 | 0 |
Investment Gains/Losses | NA | 0 | 0 | 0 | 0 |
Other Income/Charges | NA | 0 | 0 | 0 | 0 |
Income From Cont. Operations | NA | -4 | -34 | -25 | -17 |
Extras & Discontinued Operations | NA | 0 | 0 | 0 | 0 |
Net Income (GAAP) | NA | -4 | -34 | -25 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 0 | -4 | -32 | -26 | -17 |
Depreciation & Amortization (Cash Flow) | NA | 0 | 1 | 0 | 0 |
Income After Depreciation & Amortization | 0 | -5 | -33 | -27 | -17 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 1.62 | 1.37 | 0.98 | NA |
Diluted EPS Before Non-Recurring Items | NA | -20.80 | -18.60 | -17.80 | NA |
Diluted Net EPS (GAAP) | NA | -20.80 | -20.80 | -18.60 | -17.80 |
Fiscal Year end for NeuBase Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | NA | NA | 0.00 | 0.00 |
Cost Of Goods | NA | NA | NA | 0.00 | 0.00 |
Gross Profit | NA | NA | NA | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | 2.82 | 3.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 0.00 | 0.00 | -2.82 | -3.68 |
Non-Operating Income | NA | NA | NA | 0.99 | 0.24 |
Interest Expense | NA | NA | NA | 0.00 | 0.00 |
Pretax Income | NA | NA | NA | -1.82 | -3.45 |
Income Taxes | NA | NA | NA | 0.00 | 0.00 |
Minority Interest | NA | NA | NA | 0.00 | 0.00 |
Investment Gains/Losses | NA | NA | NA | 0.00 | 0.00 |
Other Income/Charges | NA | NA | NA | 0.00 | 0.00 |
Income From Cont. Operations | NA | NA | NA | -1.82 | -3.45 |
Extras & Discontinued Operations | NA | NA | NA | 0.00 | 0.00 |
Net Income (GAAP) | NA | NA | NA | -1.82 | -3.45 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | NA | 2.76 | 1.69 |
Diluted EPS Before Non-Recurring Items | NA | NA | NA | -0.95 | -1.26 |
Diluted Net EPS (GAAP) | NA | NA | NA | -0.66 | -2.04 |